Please login to the form below

Not currently logged in
Email:
Password:

fasinumab

This page shows the latest fasinumab news and features for those working in and with pharma, biotech and healthcare.

Lilly, Pfizer say NGF drug works in back pain too

Lilly, Pfizer say NGF drug works in back pain too

Pfizer/Lilly’s tanezumab – along with Regeneron/Teva’s fasinumab which reported positive phase 3 results in osteoarthritis last year – are the only NGF-targeting drugs that remain in late-stage

Latest news

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch October 2015 Deal Watch October 2015

    Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor  mAb for musculoskeletal pain (p2b).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics